Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
DTIL Stock | USD 6.21 0.66 9.61% |
About 68% of Precision BioSciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Precision BioSciences suggests that many traders are alarmed. Precision BioSciences' investing sentiment shows overall attitude of investors towards Precision BioSciences.
Precision |
Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo g
Read at businesswire.com
Precision BioSciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Precision BioSciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Precision BioSciences Fundamental Analysis
We analyze Precision BioSciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Precision BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Precision BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Precision BioSciences is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Precision BioSciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Precision BioSciences stock to make a market-neutral strategy. Peer analysis of Precision BioSciences could also be used in its relative valuation, which is a method of valuing Precision BioSciences by comparing valuation metrics with similar companies.
Peers
Precision BioSciences Related Equities
ELDN | Eledon Pharmaceuticals | 8.92 | ||||
TERN | Terns Pharmaceuticals | 3.41 | ||||
CYTK | Cytokinetics | 1.74 | ||||
HOOK | Hookipa Pharma | 1.16 | ||||
DAWN | Day One | 1.81 | ||||
MREO | Mereo BioPharma | 2.20 | ||||
ABOS | Acumen Pharmaceuticals | 2.98 | ||||
ALEC | Alector | 3.09 | ||||
DYN | Dyne Therapeutics | 3.79 | ||||
BDTX | Black Diamond | 4.63 | ||||
XFOR | X4 Pharmaceuticals | 5.13 | ||||
STOK | Stoke Therapeutics | 5.30 | ||||
PLRX | Pliant Therapeutics | 5.67 | ||||
INZY | Inozyme Pharma | 6.09 | ||||
RVMD | Revolution Medicines | 6.89 | ||||
PASG | Passage Bio | 11.88 |
Check out Precision BioSciences Hype Analysis, Precision BioSciences Correlation and Precision BioSciences Performance. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.4 | Revenue Per Share 12.872 | Quarterly Revenue Growth (0.96) | Return On Assets (0.06) | Return On Equity 0.2444 |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.